EP0513000A4 - Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate. - Google Patents

Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate.

Info

Publication number
EP0513000A4
EP0513000A4 EP19900917189 EP90917189A EP0513000A4 EP 0513000 A4 EP0513000 A4 EP 0513000A4 EP 19900917189 EP19900917189 EP 19900917189 EP 90917189 A EP90917189 A EP 90917189A EP 0513000 A4 EP0513000 A4 EP 0513000A4
Authority
EP
European Patent Office
Prior art keywords
bone
complexes
image enhancement
mri image
related tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19900917189
Other languages
German (de)
English (en)
Other versions
EP0513000A1 (fr
EP0513000B1 (fr
Inventor
Harry S Winchell
Joseph Y Klein
Elliot D Simhon
Rosa L Cyjon
Ofer Klein
Haim Zaklad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chelator LLC
Original Assignee
Concat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concat Ltd filed Critical Concat Ltd
Publication of EP0513000A4 publication Critical patent/EP0513000A4/fr
Publication of EP0513000A1 publication Critical patent/EP0513000A1/fr
Application granted granted Critical
Publication of EP0513000B1 publication Critical patent/EP0513000B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Signal Processing (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP90917189A 1989-11-27 1990-10-17 Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate Expired - Lifetime EP0513000B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44114489A 1989-11-27 1989-11-27
US441144 1989-11-27
PCT/US1990/005967 WO1991007911A1 (fr) 1989-11-27 1990-10-17 Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate

Publications (3)

Publication Number Publication Date
EP0513000A4 true EP0513000A4 (fr) 1992-09-01
EP0513000A1 EP0513000A1 (fr) 1992-11-19
EP0513000B1 EP0513000B1 (fr) 1996-07-31

Family

ID=23751720

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90917189A Expired - Lifetime EP0513000B1 (fr) 1989-11-27 1990-10-17 Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate

Country Status (10)

Country Link
EP (1) EP0513000B1 (fr)
JP (1) JP2593963B2 (fr)
AT (1) ATE140869T1 (fr)
AU (1) AU649001B2 (fr)
CA (1) CA2069638C (fr)
DE (1) DE69028001T2 (fr)
DK (1) DK0513000T3 (fr)
ES (1) ES2091251T3 (fr)
GR (1) GR3020861T3 (fr)
WO (1) WO1991007911A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885549A (en) * 1991-02-01 1999-03-23 Imarx Pharmaceutical Corp. Phosphorylated materials as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
MX9207168A (es) * 1991-12-10 1993-12-01 Dow Chemical Co Composiciones orales para inhibir la formacion de placa y de calculos.
US5555884A (en) * 1992-12-16 1996-09-17 Kabushiki Kaisha Egawa Measuring method by using resonance of a resonance medium
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
US5409689A (en) * 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
US5834456A (en) * 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
EP1637524A1 (fr) * 2004-09-20 2006-03-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dérivés de 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane 10-substitués utilisables comme agents de contraste
JP5690733B2 (ja) * 2009-08-20 2015-03-25 富士フイルムRiファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258616A1 (fr) * 1986-08-04 1988-03-09 Salutar, Inc. Imagerie RMN avec des sels de métaux polyvalents paramagnétiques de poly-(acide-alkylène-amino)-alcanes
EP0382582A1 (fr) * 1989-02-10 1990-08-16 Celltech Therapeutics Limited Tetra-aza macrocycles et leurs procédés de préparation
EP0404605A2 (fr) * 1989-06-23 1990-12-27 Celltech Therapeutics Limited Tri-aza-macrocycles et leurs procédés de préparation
EP0468634A1 (fr) * 1990-06-18 1992-01-29 The Dow Chemical Company Utilisation de complexes macrocycliques aminophosphoniques acides comme agents d'imagerie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515766A (en) * 1980-06-23 1985-05-07 The Massachusetts General Hospital Labeled phosphonic acid compositions for investigations of in vivo deposits of calcium
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3237573A1 (de) * 1982-10-09 1984-04-12 Hoechst Ag, 6230 Frankfurt Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
US4749560A (en) * 1984-08-13 1988-06-07 Research Corporation Metal organo phosphorous compounds for NMR analysis
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8518300D0 (en) * 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
GB8701054D0 (en) * 1987-01-16 1987-02-18 Amersham Int Plc Contrast agent for nmr scanning

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258616A1 (fr) * 1986-08-04 1988-03-09 Salutar, Inc. Imagerie RMN avec des sels de métaux polyvalents paramagnétiques de poly-(acide-alkylène-amino)-alcanes
EP0382582A1 (fr) * 1989-02-10 1990-08-16 Celltech Therapeutics Limited Tetra-aza macrocycles et leurs procédés de préparation
EP0404605A2 (fr) * 1989-06-23 1990-12-27 Celltech Therapeutics Limited Tri-aza-macrocycles et leurs procédés de préparation
EP0468634A1 (fr) * 1990-06-18 1992-01-29 The Dow Chemical Company Utilisation de complexes macrocycliques aminophosphoniques acides comme agents d'imagerie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 111, 1989, page 784, abstract no. 194870n, Columbus, Ohio, US; T.Ya. MEDVED et al.: "New cyclopendant organophosphorus complexons: 1,4,7-tris(beta-dihydroxyphosphorylethyl)-1,4,7-triazacylononane", & IZV. AKAD. NAUK SSSR, SER. KHIM. 1988, (9), 2107-13 *
CHEMICAL ABSTRACTS, vol. 112, 1990, page 732, abstract no. 198536b, Columbus, Ohio, US; Yu.M. POLIKARPOV et al.: "A new cyclopendant organophosphorus complexon: 1,4,7,10-tetrakis(beta-dihydroxyphosphorylethyl)-1,4,7,10-tetraazacylododecane", & IZV. AKAD. NAUK SSSR, SER. KHIM. 1989, (9), 2112-16 *
MAGNETIC RESONANCE IN MEDICINE, vol. 15, no. 1, July 1990, pages 25-32, Academic Press, Duluth, MN, US; D.C. BUSTER et al.: "Tm(DOTP)5-:A23Na+shift agent for perfused rat hearts" *

Also Published As

Publication number Publication date
ES2091251T3 (es) 1996-11-01
CA2069638C (fr) 1999-02-09
CA2069638A1 (fr) 1991-05-28
GR3020861T3 (en) 1996-11-30
WO1991007911A1 (fr) 1991-06-13
AU649001B2 (en) 1994-05-12
DE69028001D1 (de) 1996-09-05
DE69028001T2 (de) 1996-12-19
ATE140869T1 (de) 1996-08-15
DK0513000T3 (da) 1996-12-30
JPH05504127A (ja) 1993-07-01
AU6732290A (en) 1991-06-26
EP0513000A1 (fr) 1992-11-19
EP0513000B1 (fr) 1996-07-31
JP2593963B2 (ja) 1997-03-26

Similar Documents

Publication Publication Date Title
ATE262329T1 (de) Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln
FI911319A0 (fi) Polypeptidderivat.
FI922151A (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
EP0513000A4 (fr) Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate.
KR910700073A (ko) 마크로사이클릭 아미노포스폰산 착화합물, 그의 제조방법, 이를 포함하는 배합물 및 용도
ATE235921T1 (de) Phosphonate- und nicht-phosphonate einheiten enthaltende polyamino-paramagnetische-chelate fuer anwendung in mri
FI895141A0 (fi) Kelatmedel med orto-ligerande funktionalitet och deras komplexer.
FI101597B1 (fi) Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi potilaan valodynaamisessa hoidossa tai diagnosoinnissa
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
FI902901A0 (fi) Dibenzol/1,5/dioxocin-5-one-derivat, deras anvaendning i laekemedel och foerfarande foer deras framstaellning.
DK601888A (da) Anvendelse af 2-pyrimidinyl-1-piperazinderivater
EP0365956A3 (fr) Agents carcinostatiques
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
RU92016532A (ru) Бензохиназолиновые соединения, способ их получения, фармацевтическая композиция и способ лечения
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.
ATE96035T1 (de) Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.
ATE74770T1 (de) Tc-99m-w-alkylphosphinico-1-hydroxyalkan-1,1diphosphonate enthaltende praeparate zur knochenszintigraphie sowie verfahren zur herstellung dieser praeparate.
EP0480458A3 (en) Process for the preparation of pharmaceutical compositions containing viminol useful in the treatment of drug dependences
GB8810128D0 (en) Phospholipids & their use as magnetic resonance imaging contrast agents
FI964849A0 (fi) Pyridyylibisfosfonaatit käytettäväksi terapeuttisina aineena

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940502

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 140869

Country of ref document: AT

Date of ref document: 19960815

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE SA

ITF It: translation for a ep patent filed

Owner name: ING. A. GIAMBROCONO & C. S.R.L.

REF Corresponds to:

Ref document number: 69028001

Country of ref document: DE

Date of ref document: 19960905

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3020861

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2091251

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: CHELATOR LLC

Free format text: CONCAT LTD.#3205 NORTHWOOD DRIVE, SUITE 101#CONCORD, CA 94520 (US) -TRANSFER TO- CHELATOR LLC#3205 NORTHWOOD DRIVE SUITE 101#CONCORD/CA 94520 (US)

NLS Nl: assignments of ep-patents

Owner name: CHELATOR LLC

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040929

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20041004

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20041013

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20041020

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20041021

Year of fee payment: 15

Ref country code: SE

Payment date: 20041021

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20041027

Year of fee payment: 15

Ref country code: GR

Payment date: 20041027

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20041029

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20041110

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20041125

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20041130

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051017

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051017

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051018

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060503

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20051017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060630

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20060501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060630

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20051018

BERE Be: lapsed

Owner name: *CHELATOR LLC

Effective date: 20051031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960731